Remove 2016 Remove Competition Remove Prescription
article thumbnail

PBMs and insurers want your prescription money

World of DTC Marketing

For many, these coupons represent the difference between filling a prescription and going without lifesaving care, but there is a lot more here than just a co-pay coupon. Those health insurers, in turn, use the discounts to offer more competitive premiums in a bid to attract enrollees. These pricing scams hurt patients as well.

Insurance 226
article thumbnail

Katie Porter attacks pharma

World of DTC Marketing

2wo: The number of mergers and acquisitions(M&A) involving one of the top 25 firms in the pharmaceutical industry more than doubled from 2006 to 2016, and the practice doesn’t seem to be abating. So where to start… Congresswoman Porter may want to look at the percentage of generic drugs available virus branded (89%). By the way, Ms.

Pharma 187
Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Shareholders versus patients: Who is more important?

World of DTC Marketing

SKIMMERS SUMMARY: There is one and only one social responsibility of business–to use its resources and engage in activities designed to increase its profits so long as it stays within the rules of the game, which is to say, engages in open and free competition without deception or fraud. Milton Friedman.

Patients 156
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

1 For use as prescription drugs, a botanical product must be approved by the FDA: to date, only two have gained this approval. 2 It was first approved as Fulyzaq in December 2012 and in October 2016, Napo Pharmaceuticals launched the new brand, Mytesi. 3 Is two too few? 2012/1916).

Marketing 103
article thumbnail

Nine for 2023, part one: a reflection on inflection

pharmaphorum

The innovative prescription medicine industry faces a trifecta of challenges. Compared to major primary care markets of the late 1990s/early 2000s, specialty care markets see more and earlier competitive launches, and the market share achieved by each launch after is progressively reduced. Pharma boxed in?

article thumbnail

Redesigning Provider Incentives to Influence Practice Patterns and Performance

Clarify Health

There was a significant decrease in pills per prescription both for peer comparison feedback and for the combination of peer comparison and individual audit feedback. pills per prescription than non-discordant clinicians. Healthcare (2016), [link] [2] Parikh, R. Manuscript in Preparation]. [3] 3] Emanuel, Ezekiel, et al.,

article thumbnail

Pharma’s post-pandemic launch performance problem: what’s the prognosis?

pharmaphorum

The prescription medicine market has recovered from the wild swings of the early pandemic with renewed growth. Non-COVID prescription medicines didn’t stop launching during the pandemic — approvals by both the FDA and the EMA were, in fact historically high in both 2020 and 2021. The scope of the problem.

Doctors 59